1. MARKETS
  2. SECTOR : HEALTHCARE & MEDICAL EQUIPMENT SUPPLIERS
  3. INDUSTRY : MEDICAL SPECIALTIES
  4. LUCID DIAGNOSTICS INC
Lucid Diagnostics Inc
XNAS: LUCD
0.64-0.01(-1.54%)
1.9M
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Lucid Diagnostics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Lucid Diagnostics Inc share price target, revenues, EPS, net income and more

Lucid Diagnostics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Lucid Diagnostics Inc Jun-2026 Quarterly Revenue is $1 Million which is growth of 26.7% YoY.

  • NEGATIVE

    Quarterly Net Profit Lucid Diagnostics Inc Jun-2026 Quarterly Net Profit is $-12 Million which is growth of -163.3% YoY.

Lucid Diagnostics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
1.51.31.51.21.20.81.21.21110.80.2
Cost Of Rev.
1.51.61.91.71.61.62.21.71.61.71.51.61.6
Gross Profit
0-0.4-0.4-0.5-0.4-0.7-1-0.5-0.6-0.7-0.4-0.9-1.4
⌄
12.811.713.711.31111.811.411.210.610.11110.310.2
Operating Profit
-12.8-12.1-14-11.8-11.4-12.5-12.4-11.7-11.2-10.8-11.5-11.1-11.6
0.10.10.10.10.10.10.10.10.10.10.1-0-0.1
Profit Before Tax
-11.7-13.9-16.3-10.4-4.4-26.9-11.5-12.4-11-10.6-10.8-14.2-11.4
Tax
⌄
-14.7-23.6-16.3-10.4-7.9-36-11.5-12.4-11-18.1-10.8-14.2-11.4
Diluted NI Avail to Com Stockholders Ann.
-14.7-23.6-16.3-10.4-7.9-36-11.5-12.4-11-18.1-10.8-14.2-11.4
Basic EPS
-0.1-0.2-0.1-0.1-0.1-0.5-0.2-0.3-0.2-0.4-0.3-0.3-0.3
Diluted EPS After ExtraOrdinary
-0.1-0.2-0.1-0.1-0.1-0.2-0.2-0.2-0.2-0.4-0.3-0.2-0.3
Number Of Shares End
183.1140.1131.4108.29968.858.450.448.24542.441.941.8
Net Income Continuing Discontinued Operations
-11.7-13.9-16.3-10.4-4.4-26.9-11.5-12.4-11-10.6-10.8-14.2-11.4
Normalized Income
-11-10.6-12.6-10.3-10-11.2-10.9-10.1-9.7-9.4-10.4-9.3-10.3
Interest Income
0.10.10.10.10.10.10.10.10.10.10.10.10.1
Interest
000000000.20.2
Net Interest Income
0.10.10.10.10.10.10.10.10.10.10.1-0-0.1
EBIT
-11.8-14-16.4-10.5-4.5-27-11.6-12.5-11.1-10.7-10.9-14.2-11.3
EBITDA
-11.5-13.8-16.2-10.3-4.3-26.7-11.4-12.2-10.9-10.2-10.3-13.6-10.7
Reconciled Cost Of Rev.
1.31.51.81.61.51.421.61.51.51.31.51.4
Reconciled Depr.
0.20.20.20.20.20.20.20.20.20.50.60.60.6
Profit From Continuing Operations
-11.7-13.9-16.3-10.4-4.4-26.9-11.5-12.4-11-10.6-10.8-14.2-11.4
Normalized EBITDA
-11.5-13.7-16.1-10.2-4.2-26.7-7.3-11.7-10.3-9.9-10.2-13.4-10.5
*All financials are in USD Million and price data in USD

Lucid Diagnostics Inc competitor comparison and performance snapshot within industry

Lucid Diagnostics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • POSITIVE

    Annual Revenue Lucid Diagnostics Inc Dec-2025 Annual Revenue is $5 Million which is growth of 8.3% YoY.

  • NEGATIVE

    Annual Net Profit Lucid Diagnostics Inc Dec-2025 Annual Net Profit is $-58 Million which is growth of -27.4% YoY.

Lucid Diagnostics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
127.3%
-
 4.74.42.40.40.5
Cost Of Rev. Ann.
23%
-
6.66.77.163.60.6--
Gross Profit Ann.
-
-
-1.2-2-2.8-3.6-3.2-0.1--
Operating Exp. Ann.
-3.4%
41.9%
49.547.743.344.952.927.38.34.4
Operating Profit Ann.
-
-
-50.7-49.6-46.1-48.5-56.2-27.4-8.3-4.4
-
-
0.30.40.30-0.7--
Other Exp. Ann.
-
-
 -8.70.2-4.2----
PBT Ann.
-
-
-52.3-58-45.5-52.7-56.2-28.1-8.3-4.4
Tax Ann.
-
-
 
⌄
-
-
-65-70.6-53-52.7-56.2-28.1-8.3-4.4
Diluted NI Avail to Com Stockholders Ann.
-
-
-65-70.6-53-52.7-56.2-28.1-8.3-4.4
EPS Ann.
-
-
 -0.7-1.1-1.3-1.6-1.5-0.2-0.1
Diluted EPS Ann.
-
-
 -0.7-1.1-1.3-1.6-1.5-0.2-0.1
Number Of Shares End
52%
28.8%
 131.458.442.437.434.937-
Total Exp. Ann.
-1.3%
45.6%
 54.450.450.956.627.98.34.4
Net Income Continuing Discontinued Operations Ann.
-
-
-52.3-58-45.5-52.7-56.2-28.1-8.3-4.4
Normalized Income Ann.
-
-
-44.6-44-41.2-42.8-41.2-18.5-8.2-4.3
Interest Income Ann.
-
-
0.40.40.30.4----
Interest Ann.
-
-
0000.40.7--
EBITDA Ann.
-
-
-51.7-57.5-44.7-50.2-54.2-27.4-8.3-4.4
Reconciled Cost Of Rev. Ann.
23.4%
-
6.26.26.65.53.30.6--
Reconciled Depr. Ann.
-22%
-
0.90.91.22.51.9--
Profit From Continuing Operations Ann.
-
-
-52.3-58-45.5-52.7-56.2-28.1-8.3-4.4
Normalized EBITDA Ann.
-
-
-51.4-57.1-39.2-49.7-54.2-27.4-8.3-4.4
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
6.8%
2Y CAGR
39.9%
3Y CAGR
127.3%
Operating Exp. Ann.
1Y CHG
10.2%
2Y CAGR
3.1%
3Y CAGR
-3.4%
5Y CAGR
41.9%

Lucid Diagnostics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Lucid Diagnostics Inc Dec-2025 Total Shareholders Fund is $-43 Million which is growth of 11.6% YoY.

  • POSITIVE

    Total Assets Lucid Diagnostics Inc Dec-2025 Total Assets is $40 Million which is growth of 31.7% YoY.

Lucid Diagnostics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
7.5%
79%
40.430.727.332.5592.21
⌄
45.9%
13.4%
29.525.329.69.54.315.76.3
⌄
-
-
-43.3-49-20.923.154.7-13.5-5.3
Total Capitalization Ann.
-22.1%
-
10.95.4-2.323.154.7-13.5-5.3
Tangible Assets Ann.
-18.5%
-
10.64.7-3.719.654.7-13.5-5.3
Working Capital Ann.
-17.6%
-
8.91.6-7.315.953-14.3-6
Invested Capital Ann.
-
-
-19.3-30.4-723.154.7-13.5-5.3
Tangible Book Value Ann.
-
-
-43.7-49.8-22.419.654.7-13.5-5.3
Borrowings Ann.
134.5%
-
25.821.315.32---
Net Debt Ann.
-
-
-------
Share Issued Ann.
47.9%
28.8%
131.163.142.340.534.93737
Number Of Shares End
52%
28.8%
131.458.442.437.434.937-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
31.6%
2Y CAGR
21.6%
3Y CAGR
7.5%
5Y CAGR
79%
Total Current Liabilities Ann.
1Y CHG
21.7%
2Y CAGR
-1.4%
3Y CAGR
50.4%
5Y CAGR
12.7%

Lucid Diagnostics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • POSITIVE

    Book Value Per Share Lucid Diagnostics Inc Book Value Per Share is $-0 which is growth of 52.5% YoY.

  • NEUTRAL

    ROE Lucid Diagnostics Inc ROE is 0% which is growth of 0% YoY.

Lucid Diagnostics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--182.89%-176.20%-122.77%-91.77%-512.86%-427.56%
ROE Ann. %
-
-
---4,989.67%-144.42%-136.23%--
ROIC %
-
-
----54.7-73.5--
OPM Ann. %
-
-
-1,054.82%-1,059.64%-1,996.79%-14,899.47%-5,483.80%--
Inventory Turnover Ratio Ann.
-
-
-22.930.7120.9--
Asset Turnover Ann. %
-
-
-0.20.100--
Working Capital Turnover Ann.
-
-
0.52.7-0.300
Quick Ratio Ann.
-
-
-10.62.712.600
Current Ratio Ann.
-
-
-1.10.82.913.50.10.1
Interest Coverage Ratio Ann.
-
-
--1,750.1-125.6--41.6--
LT Debt To Equity Ann.
-
-
---0---
*All financials are in USD Million and price data in USD

Lucid Diagnostics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Lucid Diagnostics Inc Dec-2025 Cash From Operating Activity is $-46 Million which is growth of -5.3% YoY.

  • POSITIVE

    Net Cash Flow Lucid Diagnostics Inc Dec-2025 Net Cash Flow is $12 Million which is growth of 256.6% YoY.

Lucid Diagnostics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
-46.5-44.1-32.8-29.7-17.7-5.6-2.4
-
-
-0.2-0.7-0.2-4.1-0.9--
183.1%
60.2%
5948.329.52.672.15.62.5
Cash Plus Cash Eqv. End Of Year Ann.
15.5%
222.2%
34.722.418.922.553.70.10.2
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
12.43.5-3.6-31.253.5-0.10.1
Cash Plus Cash Eqv. Begin Of Year Ann.
-25.3%
156.9%
22.418.922.553.70.10.20
Income Tax Paid Supplemental Data Ann.
-
-
-------
Interest Paid Supplemental Data Ann.
-
-
-------
Capex Ann.
-
-
-0.2-0.7-0.2-0.9-0.9--
Issuance Of Capital Stock Ann.
218.9%
-
58.429.818.91.870--
Issuance Of Debt Ann.
-
-
0.421.610----
Repayment Of Debt Ann.
-
-
-3.6-----
Repurchase Of Capital Stock Ann.
-
-
-------
Free Cash Flow Ann.
-
-
-46.7-44.8-33-30.6-18.5-5.6-2.4
*All financials are in USD Million and price data in USD
Cash from Financing Act. Ann.
1Y CHG
22.2%
2Y CAGR
41.4%
3Y CAGR
183.1%
5Y CAGR
60.2%